https://orcid.org/0000-0001-6810-0284
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Rong Liu, Ying Yuan, Suman Sen, Xin Yang, Qi Jiang, Xiaoyun (Nicole) Li, Chengxing (Cindy) Lu, Mithat Gönen, Hong Tian, Heng Zhou, Ruitao Lin & Olga Marchenko. (2022) Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials. Statistics in Biopharmaceutical Research 14:3, pages 270-282.
Read now
Read now
Nigel Stallard, Lisa Hampson, Norbert Benda, Werner Brannath, Thomas Burnett, Tim Friede, Peter K. Kimani, Franz Koenig, Johannes Krisam, Pavel Mozgunov, Martin Posch, James Wason, Gernot Wassmer, John Whitehead, S. Faye Williamson, Sarah Zohar & Thomas Jaki. (2020) Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research 12:4, pages 483-497.
Read now
Read now
Articles from other publishers (8)
Pavel Mozgunov, Suzie Cro, Anne Lingford‐Hughes, Louise M. Paterson & Thomas Jaki. (2021) A dose‐finding design for dual‐agent trials with patient‐specific doses for one agent with application to an opiate detoxification trial. Pharmaceutical Statistics 21:2, pages 476-495.
Crossref
Crossref
Sean Ewings, Geoff Saunders, Thomas Jaki & Pavel Mozgunov. (2022) Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic. BMC Medical Research Methodology 22:1.
Crossref
Crossref
Saye H Khoo, Richard Fitzgerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods, Helen Reynolds, Ellice Marwood, Pavel Mozgunov, Emily Adams, Katie Bullock, Wayne Holman, Marcin D Bula, Jennifer L Gibney, Geoffrey Saunders, Andrea Corkhill, Colin Hale, Kerensa Thorne, Justin Chiong, Susannah Condie, Henry Pertinez, Wendy Painter, Emma Wrixon, Lucy Johnson, Sara Yeats, Kim Mallard, Mike Radford, Keira Fines, Victoria Shaw, Andrew Owen, David G Lalloo, Michael Jacobs & Gareth Griffiths. (2021) Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. Journal of Antimicrobial Chemotherapy 76:12, pages 3286-3295.
Crossref
Crossref
Lisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, Erwin S. Schultz, Daniela Göppner, Chalid Assaf, Dietrich Trebing, Kai Stelter, Christine Windemuth-Kieselbach, Selma Ugurel & Dirk Schadendorf. (2021) Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. European Journal of Cancer 158, pages 72-84.
Crossref
Crossref
Ankeet Shah, Dominic Grimberg & Brant A. Inman. 2021. Nanoparticle-Mediated Immunotherapy. Nanoparticle-Mediated Immunotherapy
51
66
.
Pavel Mozgunov & Thomas Jaki. (2019) Improving safety of the continual reassessment method via a modified allocation rule. Statistics in Medicine 39:7, pages 906-922.
Crossref
Crossref
Michael J Grayling, Munyaradzi Dimairo, Adrian P Mander & Thomas F Jaki. (2019) A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials. JNCI: Journal of the National Cancer Institute 111:12, pages 1255-1262.
Crossref
Crossref
Delou, Souza, Souza & Borges. (2019) Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells 8:9, pages 1013.
Crossref
Crossref